Tempus AI (TEM) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Toronto, Ontario--(Newsfile Corp. - November 12, 2026) - Arizona Eagle Mining Corp. (TSXV: AZEM) (OTCQB: AZEMF) (the "Company" or "Arizona Eagle") is pleased to announce the completion of a 708 line-kilometre airborne ti…

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting takin…

SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- SOTERIA Precision Medicine Foundation , a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver personalized, data-driven cancer treatme…

Tempus is rated 'hold' as current valuation already prices in considerable future success. The platform's core strength lies in connecting diagnostic data with clinical outcomes, enhancing research value and recurring re…

Tempus AI delivered robust Q3 results, with 23% YoY revenue growth and an inflection after four quarters of deceleration. Diagnostics volumes surged, notably MRD tests up 300% YoY, while Data & Applications revenue accel…

Tempus AI NASDAQ: TEM is among the more volatile AI-related stocks, trading in a wide range and testing upper limits several times since its IPO. Volatility stems from several factors, including the path to profitability…

Tempus AI raises its 2026 revenue outlook as oncology demand, expanding data partnerships and reimbursement-driven pricing gains fuel growth prospects for 2027.…

Baron SMID Cap ETF returned -2.87% (NAV) in the third quarter, outperforming its benchmark, the Russell 2500 Growth Index, which returned -10.35%. Top contributors were Rubrik, Inc., Tempus AI, Inc., and Netskope, Inc. T…

Tempus AI Inc. (NASDAQ:TEM) on Monday posted upbeat results for the third quarter.…

Tempus AI (NASDAQ:TEM | TEM Price Prediction) was trading higher this afternoon. It sat at $80.31, up 11.21% after the precision medicine company reported third-quarter results before the open.…

Tempus AI, Inc. (TEM) Q3 2026 Earnings Call Transcript…

Tempus AI Inc. (NASDAQ:TEM) shares were trading higher on Monday after the company reported third-quarter adjusted earnings of 7 cents per share, swinging from a loss of 8 cents, beating the consensus per-share loss of 1…

The headline numbers for Tempus (TEM) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago…

Tempus AI (TEM) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to a loss of $0.11 per share a year ago.…

Tempus AI NASDAQ: TEM reported third-quarter 2026 revenue of $411.5 million, up 23% from a year earlier, as growth in oncology diagnostics and data-and-applications services continued to drive results. The company also r…

Data and Applications revenue grew 33% and earns gross margins above 71%, so its faster growth lifts company-wide margins. The adjusted EBITDA outlook held at about $65 million, implying a jump to roughly $34 million in …

Tempus AI reported better-than-expected third-quarter earnings.…

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026. “Q3 was a…

P3 Health Partners (NASDAQ: PIII - Get Free Report) and Tempus AI (NASDAQ: TEM - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the streng…

Tempus AI, Inc. (NASDAQ: TEM - Get Free Report) CEO Eric Lefkofsky sold 250,000 shares of the stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $70.36, for a total value of $17,…

Tempus AI or Doximity: Which medical information systems stock offers better value? Compare growth prospects, AI expansion, earnings estimates and valuation.…

Tempus AI (NASDAQ:TEM | TEM Price Prediction) reports third-quarter results around Nov. 2. The company has a $1.5 billion Personalis (NASDAQ:PSNL) deal pending, and shares are down 20.36% over the past month.…

Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that its xR assay has received certification under the European Union's In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic devic…

NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, “BMS”) an…

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS will license multimodal oncology data from Tempus thr…

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced results from a study evaluating an AI-enabled pre-screening panel for patients with advanced non-small cell lung cancer (NSCLC). The panel achieved …

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the third quarter ended Septemb…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 24. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

